O slideshow foi denunciado.
Seu SlideShare está sendo baixado. ×

Bronchial Asthma slide share ppt

Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Próximos SlideShares
8.Asthma
8.Asthma
Carregando em…3
×

Confira estes a seguir

1 de 41 Anúncio

Mais Conteúdo rRelacionado

Semelhante a Bronchial Asthma slide share ppt (20)

Mais recentes (20)

Anúncio

Bronchial Asthma slide share ppt

  1. 1. Seminar on; Management of Bronchial Asthma Prepared by Dr. Atinkut Abesha. Moderator Dr. Girma (MD, Assistant professor of I. Medicine) Date: 27/04/2014 E.C Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 1
  2. 2. Objectives To know about definition of Asthma To know about pathophysiology of Asthma To know approaches to management of B. Asthma Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 2
  3. 3. Outlines Introduction Etiology and Risk factors of Asthma Pathophysiology of Asthma Classification of Asthma Clinical presentations of Asthma Diagnosis Management of Asthma Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 3
  4. 4. Case scenario 1 Mr. X a 21 years old male patient presented with SOB, chest tightness, and dry cough of 01 week duration which was exacerbated during cold weather. Those symptoms came 1x/month. Associated to this he has hx of sneezing, rhinorrhea and nasal congestion. He has also recurrent hx of itching sensation around his nose. He has also family hx of Asthma, DM and HTN from his father. He did not took any medication before for those symptoms. 4 Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern)
  5. 5. Case scenario 1… Cont P/E: G/A: ASL V/S: BP= 110/70, PR= 105, RR=28, T=36.9, SPO2= 91% with ATM R/S: scattered wheezing on posterior chest bilaterally N/S: COTPP Investigation: CBC: WBC= 9.2, N=78%, E=8.1, Hgb=12.1, Hct=37.9, MCV=84.2, PLT= 274 CXR=Unremarkable Mgt: Salbutamol 6 PUFF PRN, prednisolone 40 mg/day for 01 week 5 Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern)
  6. 6. Case scenario 1… Cont 1. What will be the possible Dx (Diagnostic flow chart)? 2. How do we assess the patient (Based on parameters)? 3. Where is her step of treatment 4. How do we manage the patient (Step up and Step down approach)? 5. Comment on the treatment which was given to the patient? 6 Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern)
  7. 7. Case scenario 2 Ms. Y: a 28 years old known Asthmatic patient for the last 06 months duration who was on Budesonide: Formotelol (Symbicort) which was taken 2 PUFF twice daily and Salbutamol 6 PUFF PRN presented with exacerbation of SOB of 02 day duration. Associated to this she has hx of whitish productive cough, audible breath sound, chest tightness, LGIF of the same duration. She also had hx of night time wake up 1x/wk . She has also previous hx of similar attack 02/month. Othewise no hx of DM and HTN 7 Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern)
  8. 8. Case scenario 2… Cont P/E: G/A: ASL INO2 V/S: BP= 120/70, PR= 110, RR=30, T=36.8, SPO2= 96% with 4L & 82%ATM R/S: diffuse wheezing on posterior chest bilaterally N/S: COTPP Investigation: CBC: WBC= 17.21, N=94%, E=1.6, Hgb=16.7, Hct=48.9, MCV=92.3, PLT= 280 CXR= Hyper inflated lung 8 Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern)
  9. 9. Case scenario 2… Cont 1. What will be the possible Dx (Diagnostic flow chart)? 2. How do we assess the patient (Based on parameters)? 3. Where is her step of treatment 4. How do we manage the patient (Step up and Step down approach)? 5. Comment on the treatment which was given to the patient? 9 Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern)
  10. 10. Introduction… Def… Asthma; a disease characterized by episodic airway obstruction and airway hyperresponsiveness usually accompanied by airway inflammation Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 10
  11. 11. Introduction… Epidemiology… ∼241 million people affected globally (Worldwide; 4.3%) More prevalent among children (8.4%) than adults (7.7%) Childhood M: F; 2:1, but Adulthood greater prevalence in women  Mortality rate globally 0.19/100,000 Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 11
  12. 12. Etiology and Risk factors of Bronchial Asthma Allergen exposure Occupational exposure Air pollution Infections Tobacco Obesity Diet Irritants High intensity exercise in elite athletes Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 12
  13. 13. Pathophysiology of Bronchial Asthma Histology of Bronchus; Mucosa Muscularis mucosae Submucosa Cartilaginous layer Adventitia Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 13
  14. 14. Pathophysiology of Bronchial Asthma ghyjkv Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 14
  15. 15. Pathophysiology of Bronchial Asthma . Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 15
  16. 16. Pathophysiology of Bronchial Asthma Airway hyperresponsiveness is a hallmark of asthma; Bronchoconstriction airway inflammation, and Mucous impaction Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 16
  17. 17. Classification of Bronchial Asthma Intermittent Persistent Based on Severity (symptoms) Mild Moderate Sever Childhood onset Asthma Based on age of Onset Adult onset Asthma Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 17
  18. 18. Clinical Presentations of Bronchial Asthma History of respiratory symptoms Wheeze Chest tightness Vary over time and in intensity Shortness of breath Cough Variable expiratory airflow limitation Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 18
  19. 19. Diagnosis of Bronchial Asthma History Physical Examination Investigation  Pulmonary Function Tests Eosinophil Counts IgE Skin Tests Radioallergosorbent Tests Exhaled Nitric Oxide Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 19
  20. 20. Diagnosis of B.Asthma…Investigation Spirometry; Assess how well the lungs work by measuring lung volume, capacity, rates of flow, and gas exchange Confirms Variable Expiratory Air flow limitations FEV1, FEV1/FVC Diurnal PEF variability Lung function after treatment Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 20
  21. 21. Diagnosis of B.Asthma…Investigation Spirometry; Helps to differentiate Obstructive or Restrictive Lung diseases Characteristics Obstructive Restrictive FEV1 <80% of the predicted normal <80% of the predicted normal FVC but to a lesser extent than FEV1 <80% of the predicted normal FEV1/FVC <0.7 >0.7 Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 21
  22. 22. Diagnosis of B.Asthma…Investigation Spirometry; Clues b/n obstructive lung diseases Characteristics Spirometry for Asthma Spirometry for COPD FEV1 Increases by 12% after BD Doesn’t Increase by 12% after BD FVC May or May not be reduced Always Reduced FEV1/FVC Less than 70% Less than 70 % Serial Spirometry Vary or remain similar over time Deterioration in values in time Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 22
  23. 23. Diagnosis of B.Asthma…Investigation Spirometry; Once the diagnosis of asthma has been made, the main role of lung function testing is for the assessment of future risk. It should be recorded;  At diagnosis 3–6 months after starting treatment Periodically thereafter. Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 23
  24. 24. Diagnosis of B.Asthma…Diagnostic flowchart Patient with respiratory symptoms. Are they typical of Asthma? Detailed Hx & P/E for Asthma. Are they supports Asthma Dx? Is patient already taking asthma controller treatment? Perform Spirometry /PEF with reversibility test. Is result support Asthma Dx? Treat for Asthma No Further Hx & Test for alternative DX Treat for Alternative Dx Y e s No - Arrange other tests -Confirm Asthma Dx Consider trial of treatment for most likely Dx or refer for further investigations yes yes No N o No Y e s Yes No yes Dx step es for Cont rolle r t/t Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 24
  25. 25. Diagnosis of B.Asthma…Diagnostic flowchart Is patient already taking asthma controller treatment? Variable respiratory symptoms and variable airflow limitation Variable respiratory symptoms but no variable airflow limitation Few respiratory symptoms, normal lung function and no variable airflow limitation Persistent shortness of breath and persistent airflow limitation 1 2 3 4 Diagnosis of asthma is confirmed Assess the level of asthma control Consider repeating Spirometry 1. If FEV1 is >70% predicted, stepping down &reassess after 2-4wks 2. If FEV1 is <70% predicted, stepping up for 3 months 1. Symptom emerge and lung function falls: asthma is confirmed…. Step Up Consider stepping down 2. ceasing controller if no change in symptoms or lung function (1 year follow up) Consider stepping up for 3 months Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 25
  26. 26. Assessment of Asthma Asses Asthma control Asses Asthma severity Asses Comorbidity Asses treatment issues Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 26
  27. 27. Assessment of Asthma I. Assessment of Asthma control Asthma control is assessed in two domains: Symptom control (In the past 4 weeks) Frequency of daytime asthma symptoms (>2/wk) Any night waking due to asthma For patients using SABA, frequency of SABA use (>2/wk) Any Activity limitation due to Asthma Well controlled, Partly controlled, Uncontrolled Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 27
  28. 28. Assessment of Asthma I. Assessment of Asthma control Risk of adverse outcomes (Exacerbations) ≥1 exacerbation in the previous year Socioeconomic problems Poor adherence High SABA use Incorrect inhaler technique Low Lung function test Exposure Type II inflammatory mediators like blood eosinophilia Other medical conditions Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 28
  29. 29. Assessment of Asthma II. Asthma severity Mild Moderate Sever Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 29
  30. 30. Assessment of Asthma III. Comorbidities Contribute to symptoms and poor quality of life, and sometimes to poor asthma control Rhinitis Rhinosinusitis GERD Obesity OSA Depression Anxiety Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 30
  31. 31. Assessment of Asthma IV. Treatment issues Inhaler technique Written asthma action plan Patient’s attitudes and goals for their asthma and medications Document the patient’s current treatment step Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 31
  32. 32. Management of Bronchial Asthma Goals of management To achieve good symptom control To minimize future risk of asthma-related mortality To minimize exacerbations To minimize persistent airflow limitation To minimize side-effects of treatment Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 32
  33. 33. Management of Bronchial Asthma In order to achieve the above goals; Non pharmacological treatment Pharmacological treatment Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 33
  34. 34. Management of Bronchial Asthma I. Non pharmacological treatment Reducing triggers Treating modifiable risk factors Vaccination Bronchial thermoplasty Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 34
  35. 35. Management of Bronchial Asthma II. Pharmacological treatment Bronchodilators (β2 -agonists, anticholinergics, and theophylline) Controllers (Anti-Inflammatory/Antimediator); Costicosteroids Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 35
  36. 36. Management of Bronchial Asthma II. Pharmacological treatment Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 36
  37. 37. Management of Bronchial Asthma For adults and adolescents step Up/Down approach Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 37
  38. 38. Management of Bronchial Asthma Patients should be seen 1–3 months after starting treatment Every 3–12 months thereafter. After an exacerbation, a review visit within 1 week should be scheduled Stepping down treatment when; Asthma is well controlled for 2–3 months and Lung function has reached a plateau N.B. Complete cessation of ICS is associated with a significantly increased risk of exacerbations Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 38
  39. 39. Management of Bronchial Asthma It involves a continual cycle that involves assessment, treatment and review by appropriately trained personnel Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 39
  40. 40. References Harrison’s principles of Internal Medicine 21st edition GINA, 2022 updated Up to date 2018 Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) 40
  41. 41. Management of Bronchial Asthma; BY: Atinkut A. (Medical Intern) Thanks A Lot!!! 41 1 1 2 2 + 3

Notas do Editor

  • in those with a predisposition to atopy
  • Mucosa, lining the inside of the bronchus.
    Muscularis mucosae, a smooth muscle layer under the mucosa.
    Submucosa, a connective tissue layer with seromucous glands.
    Cartilaginous layer, a layer of cartilage plates located beneath the submucosa.
    adventitia, the deepest layer separating the bronchus from surrounding tissues
  • Most commonly, this
    inflammation is eosinophilic in nature. In some patients, neutrophilic
    inflammation may be predominant, especially in those with more
    severe asthma. Mast cells are also more frequent. Many
    inflammatory cells are present in an activated state, as will be
    discussed in the section on inflammation.
  • . It is defined as an acute narrowing response of the airways in reaction to agents that do not elicit airway responses in nonaffected individuals or an excess narrowing response to inhaled agents as compared to that which would occur in nonaffected individuals
  • An estimated 5–20% of new cases of adult-onset asthma can be attributed to occupational exposure

    Mild persistent: symptoms of asthma occur no more than two days per week or two times per month.
    Moderate persistent: Increasingly severe symptoms of asthma occur daily and at least one night each week
    Sever persistent :symptoms occur several times per day almost every day
  • more than one-third of patients with a physician diagnosis of asthma do not meet the criteria for the diagnosis.
    Physical Examination In between acute attacks, physical findings may be normal. Many patients will have evidence of allergic rhinitis with pale nasal mucus membranes. Five percent or more of patients may have nasal polyps, with increased frequency in those with more severe asthma and aspirin-exacerbated respiratory disease. Some patients will have wheezing on expiration (less so on inspiration). During an acute asthma attack, patients present with tachypnea and tachycardia, and use of accessory muscles can be observed. Wheezing, with a prolonged expiratory phase, is common during attacks, but as the severity of airway obstruction progresses, the chest may become “silent” with loss of breath sounds.
  • Spirometry Reading
    Sometimes abnormal but may be normal in allergic induced asthma
    Always abnormal
  • Consider repeating spirometry after withholding BD (4 hrs for SABA, 24 hrs for twice-daily ICSLABA, 36hrs for once-daily ICS-LABA) or during symptoms. Check between-visit variability of FEV1, and bronchodilator responsiveness. If still normal, consider other diagnoses (Box 1-5, p.27). If FEV1 is >70% predicted: consider stepping down controller treatment (see Box 1-5) and reassess in 2–4 weeks, then consider bronchial provocation test or repeating BD responsiveness. If FEV1 is

×